News

Upon completion of the acquisition, which is subject to definitive agreements, Enzo will have local, directly owned presence from which to market its growing line of life sciences

The study is designed to evaluate the safety and efficacy of Actelion-1 in delaying disease progression and mortality in patients with pulmonary arterial hypertension (PAH). The SERAPHIN study

The iChem Velocity system is the first urinalysis system to employ Iris’s proprietary Kinetic Imaging technology that will optimize the sensitivity and dynamic range of the company’s urine

The European Commission approved Retacrit on the basis of strong, compelling safety and efficacy data, as well as compliance with extensive quality, clinical and non-clinical guidelines. Retacrit has

Under the terms of the agreement, Santaris Pharma will grant GlaxoSmithKline (GSK) options to drug candidates discovered and developed under the collaboration in up to four different viral

“Tower’s superb technology and its leadership in the CIS X-ray area, combined with CMT’s leadership in digital X-ray imaging system allow both companies to target and expand into

The company believes that the tumor growth inhibition observed in pre-clinical studies is due to a specific binding of BL-2030 to CCL2. By inhibiting CCL2’s activity, BL-2030 impairs

Under the terms of the agreement, Axentis Pharma purchased from aRigen Pharmaceuticals an exclusive license for the development and commercialization of ARB-CF0223 worldwide except Japan and Korea. As

On March 1, 2007, Samaritan signed an exclusive licensing agreement with Shire Human Genetic Therapies to market and sell Elaprase in Greece and Cyprus. Since the launch of